2017 China Biopharmaceutical Industry Report

  • ID: 4415709
  • Report
  • Region: China
  • 30 Pages
  • Cipher Ground
1 of 4
The Biopharmaceutical Industry Is a Thriving Sector in China, Forecasted to Grow to About 15% of GDP in 2030

This report provides a complete and detailed analysis of the biopharmaceutical sector for China. We present in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

China is the world’s second largest pharmaceutical market after the US and is expected to overtake the US by 2020. The biopharmaceutical industry is a thriving sector in China, forecasted to grow to about 15% of GDP in 2030, becoming an important economic growth point. China is moving from primarily a generic market to a global biopharmaceutical market. 

At present, China has gathered all the three critical factors that will boost the innovation of China’s biopharmaceutical industry: “Right time, Right place, and Right people”. On the road to innovation, however, China still has a lot of things to do, including:

  • Speeding up pharmaceutical policy reform
  • R & D internationalization
  • Development of cross-border technology intermediary
  • Accelerating therealization of the “Healthy China 2030” strategic

Key Topics Covered:

  • The Rise of China’s Biopharmaceutical Industry
  • Challengesof China’s Biopharmaceutical Industry
  • Unprecedented Strategic Height of the Biopharmaceutical Industry
  • Vast Opportunities in China’s Biopharmaceutical Industry
  • High-Tech Development Zone – An Important Platform
  • Trillion-Dollar China Market
  • High-Tech Development Zone: Innovation Hub
  • Entrepreneurship of Overseas Talents Fuels Innovation
  • Increasing Values of Overseas Talents
  • Smart Investors Discover Talents
  • On the Road to Innovation
Note: Product cover images may vary from those shown
2 of 4

1. Executive Summary

2. Background

  • The Rise of China's Biopharmaceutical Industry
  • Challenges of China's Biopharmaceutical Industry
    • Big but Weak
    • Lack of Innovation
    • Unstable Financing

3. Three Critical Factors Boosting Biopharmaceutical Innovation

  • Right Time
    • Unprecedented Strategic Height of the Biopharmaceutical Industry
    • Vast Opportunities in China's Biopharmaceutical Industry
      • Government's Generous Investment in Biopharmaceutical Sector
      • Huge Room for Improvement in GDP Share of Health Expenditure
  • Right Place
    • Trillion-Dollar China Market
    • High-Tech Development Zone: Innovation Hub
  • Right People
    • Entrepreneurship of Overseas Talents Fuels Innovation
    • Increasing Values of Overseas Talents
    • Smart Investors Discover Talents

4. On the Road to Innovation

  • Groundbreaking Policy Reform
  • Foster R& D Investment
  • Strengthen R& D Internationalization
  • Overseas M & A: A Shortcut to Innovation
  • Innovation Impetus: Technology Intermediary

5. Conclusion

6. Opinion

  • Borrowing Overseas Chickens to Lay Eggs
  • Technology Intermediary is the Catalyst to Innovation
  • Building not Buying Companies
  • Forward Approach: Accepting Nature's Gift
  • Magic Ore: Marine Drugs
  • Growing Medicine in Plants

7. Source

8. Abbreviations

9. About

10. Contact

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll